Long term efficacy of first-line afatinib and the clinical utility of ctDNA monitoring in patients with suspected or confirmed EGFR mutant non-small cell lung cancer who were unsuitable for chemotherapy: Clinical Studies.
Saved in:
| Title: | Long term efficacy of first-line afatinib and the clinical utility of ctDNA monitoring in patients with suspected or confirmed EGFR mutant non-small cell lung cancer who were unsuitable for chemotherapy: Clinical Studies. |
|---|---|
| Authors: | Popat, Sanjay1 (AUTHOR), Januszewski, Adam2 (AUTHOR), O'Brien, Mary1,3 (AUTHOR), Ahmad, Tanya4 (AUTHOR), Lewanski, Conrad3 (AUTHOR), Dernedde, Ulrike5 (AUTHOR), Jankowska, Petra6 (AUTHOR), Mulatero, Clive7 (AUTHOR), Shah, Riyaz8 (AUTHOR), Hicks, Jonathan9 (AUTHOR), Geldart, Tom10 (AUTHOR), Cominos, Mathilda11 (AUTHOR), Gray, Gill12 (AUTHOR), Spicer, James13 (AUTHOR), Bell, Karen9 (AUTHOR), Roitt, Simon14 (AUTHOR), Morris, Clive14 (AUTHOR), Ngai, Yenting15 (AUTHOR), Hughes, Laura15 (AUTHOR), Hackshaw, Allan15 (AUTHOR) |
| Source: | British Journal of Cancer. Feb2025, Vol. 132 Issue 3, p245-252. 8p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
